Erasca, Inc. (ERAS) Stock Forecast

NASDAQ: ERASAnalyst ratings, price target and estimates.

ERAS analyst forecast

as of October 18, 2026
Analyst consensus
Buy
4.33 / 5 from 9 analysts
Price target
$24.11
average of analyst targets
Upside to target
+80.1%
from the latest close
Next earnings
November 11, 2026
EPS estimate $-0.14
52-week range
$2.20 – $22.47

ERAS analyst ratings

9 analysts
Strong buy
556%
Buy
222%
Hold
222%
Sell
00%
Strong sell
00%

Number of analysts at each rating.

ERAS price target

Price $13.39Target $24.11
52-week low $2.2052-week high $22.47

The average of analyst 12-month price targets compared with the latest close and the 52-week range.

ERAS earnings per share estimates

Erasca, Inc. EPS estimates
PeriodAverageLowHighYear agoGrowthAnalysts
Current quarter (Sep '26)−$0.13−$0.14−$0.09−$0.11−18.3%8
Current fiscal year (2026)−$0.98−$1.06−$0.86−$0.44−121.9%8
Next fiscal year (2027)−$0.62−$0.80−$0.34−$0.98+36.2%8

Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.

ERAS revenue estimates

Erasca, Inc. revenue estimates
PeriodAverageLowHighGrowthAnalysts
Current quarter (Sep '26)$0$0$00.0%6
Current fiscal year (2026)$0$0$00.0%6
Next fiscal year (2027)$0$0$00.0%6

ERAS EPS: reported and forecast

Reported EPSEstimate (average; low–high)

Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.

ERAS EPS estimate revisions

Erasca, Inc. EPS estimate revisions
Period90 days ago60 days ago30 days ago7 days agoNowChange (90 d)Revisions (30 d)
Current quarter (Sep '26)−$0.12−$0.12−$0.12−$0.13−$0.13+5.4%2 up · 5 down
Current fiscal year (2026)−$0.97−$0.97−$0.95−$0.97−$0.98+1.1%3 up · 6 down
Next fiscal year (2027)−$0.57−$0.57−$0.56−$0.60−$0.62+8.5%2 up · 7 down

How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.

ERAS earnings surprises

Reported EPSEstimate

Reported EPS vs the consensus estimate for the last 12 quarters; ERAS beat in 7 of 12.

What analysts expect from ERAS

9 analysts cover Erasca; their consensus rating is buy (4.33 on a 1–5 scale, where 5 is a strong buy). The average price target is $24.11, 80.1% above the latest close of $13.39. Analysts expect earnings of −$0.98 per share for 2026, −121.9% from a year earlier. For 2027 the average estimate is −$0.62 per share. Erasca beat the EPS estimate in 7 of the last 12 quarters.

Related: ERAS income statement, ERAS key metrics, ERAS chart. See the ERAS stock overview for the latest quote and news.

ERAS forecast FAQ

What is Erasca's price target?

The average analyst price target for Erasca is $24.11, 80.1% above the latest close of $13.39.

Is Erasca a buy, hold or sell?

Of 9 analysts covering Erasca, 5 rate it a strong buy, 2 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.

What is Erasca's EPS forecast?

Analysts forecast −$0.98 per share for 2026 (range −$1.06 to −$0.86); for 2027 the estimate is −$0.62.

When does Erasca report earnings?

Erasca is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 after the market closes; the EPS estimate is $-0.14.

Does Erasca usually beat earnings estimates?

Erasca reported EPS at or above the analyst estimate in 7 of the last 12 quarters.

Biotechnology: forecast